On the practical aspects of large-scale production of 177Lu for peptide receptor radionuclide therapy using direct neutron activation of 176Lu in a medium flux research reactor: the Indian experience
- 29 April 2014
- journal article
- Published by Springer Nature in Journal of Radioanalytical and Nuclear Chemistry
- Vol. 302 (1) , 233-243
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- 177Lu-DOTATATE therapy in patients with neuroendocrine tumours: 5 years’ experience from a tertiary cancer care centre in IndiaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2014
- Preparation of DOTA-TATE and DOTA-NOC freeze-dried kits for formulation of patient doses of 177Lu-labeled agents and their comparison for peptide receptor radionuclide therapy applicationJournal of Radioanalytical and Nuclear Chemistry, 2014
- Options to meet the future global demand of radionuclides for radionuclide therapyNuclear Medicine and Biology, 2013
- Radiometals for Combined Imaging and TherapyChemical Reviews, 2012
- Emergence and present status of Lu-177 in targeted radiotherapy: the Indian scenarioRadiochimica Acta, 2011
- Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine TumorsSeminars in Nuclear Medicine, 2010
- Comparative studies of 177Lu–EDTMP and 177Lu–DOTMP as potential agents for palliative radiotherapy of bone metastasisApplied Radiation and Isotopes, 2008
- 177 Lu-EDTMP: A Viable Bone Pain Palliative in Skeletal MetastasisCancer Biotherapy and Radiopharmaceuticals, 2008
- Results of Individual Patient Dosimetry in Peptide Receptor Radionuclide Therapy with 177 Lu DOTA-TATE and 177 Lu DOTA-NOCCancer Biotherapy and Radiopharmaceuticals, 2007
- Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotateEuropean Journal of Nuclear Medicine and Molecular Imaging, 2003